C5 and infection: Supplemental Table 2 shows that hemolytic events frequently coincide with records of infections despite appropriate dosing of Eculizumab. This indicates that hemolysis during infections was not caused by low Eculizumab concentrations in circulation but by exacerbated residual TP activity. Indeed, in the hemolytic sample of patient #14 we could experimentally verify an excess of Eculizumab over C5 (Figure 2D).